Startup Doctolib’s Value Falls 38% in Secondary Sale

Employees and early investors in French health-care startup Doctolib have sold shares in the company worth about €300 million ($345 million), the company said.

The secondary share sale values Doctolib at €3.6 billion, according to a person familiar with the matter, a steep discount compared to its last disclosed valuation of €5.8 billion in 2022 following an equity raise.